Eliza Barclay reveals a major breakthrough in marijuana research for NPR:
… Read the rest
Stoners and scientists alike may be stoked to learn that a startup biotech company has completed the DNA sequence of Cannabis sativa, or marijuana. But here’s something that could ruin a high: The company hopes the data will help scientists breed pot plantswithout much THC, the mind-altering chemical in the plant. The goal is instead to maximize other compounds that may have therapeutic benefits.
Kevin McKernan, founder and chief executive officer of the startup, called Medicinal Genomics, says Cannabis sativa has 84 other compounds that could fight pain or possibly even shrink tumors. But anti-marijuana laws make it difficult for scientists to breed and study the plant in most countries. That’s one reason he decided to publish his data for free on Amazon’s EC2, a public data cloud.
McKernan, who has an office in Massachusetts and a lab in the Netherlands where he can legally gather DNA from marijuana plants, has spent most of his career studying tumors in humans.